Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy

被引：8

作者：

Sommer, W. H. ^{[1
,2
]}

Ganiere, V. ^{[2
]}

Gachoud, D. ^{[2
]}

Keta, A. ^{[3
]}

Abou-Hajar, A. ^{[4
]}

Dudler, J. ^{[5
]}

Aujesky, D. ^{[2
]}

机构：

[1] Univ Munich, Dept Clin Radiol, D-81377 Munich, Germany

[2] Univ Lausanne, Div Internal Med, Lausanne, Switzerland

[3] Univ Lausanne, Div Clin Pharmacol, Lausanne, Switzerland

[4] Univ Lausanne, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland

[5] Univ Lausanne, Div Rheumatol, Lausanne, Switzerland

来源：

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2008年 / 37卷 / 04期

关键词：

D O I：

10.1080/03009740801908001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report the case of a patient receiving subcutaneous methotrexate (MTX) treatment for rheumatoid arthritis (RA) who developed a complex pattern of neurological and pulmonary symptoms. Fluctuant dysarthria, magnetic gait, weakness and dysmetria of the lower limbs, as well as symptoms and signs consistent with a diagnosis of pneumonitis started within 6 weeks of initiating MTX treatment and slowly resolved after its discontinuation. This case highlights the fact that even the relatively low doses of MTX in the therapy of RA can produce neurotoxicity, which can become manifest in a broad range of symptoms.

引用

页码：306 / 309

页数：4

共 16 条

[1] Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis - A multicenter, case-control study [J].

Alarcon, GS ;

Kremer, JM ;

Macaluso, M ;

Weinblatt, ME ;

Cannon, GW ;

Palmer, WR ;

StClair, EW ;

Sundy, JS ;

Alexander, RW ;

Smith, GJW ;

Axiotis, CA .

ANNALS OF INTERNAL MEDICINE, 1997, 127 (05) :356-+

[2]

Aplin CG, 1999, CLIN EXP DERMATOL, V24, P23

[3] Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice [J].

Grove, ML ;

Hassell, AB ;

Hay, EM ;

Shadforth, MF .

QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (06) :309-319

[4] Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis - A multicenter study with literature review [J].

Kremer, JM ;

Alarcon, GS ;

Weinblatt, ME ;

Kaymakcian, MV ;

Macaluso, M ;

Cannon, GW ;

Palmer, WR ;

Sundy, JS ;

StClair, EW ;

Alexander, RW ;

Smith, GJW ;

Axiotis, CA .

ARTHRITIS AND RHEUMATISM, 1997, 40 (10) :1829-1837

[5]

Lo Nigro L, 2000, MED PEDIATR ONCOL, V35, P449, DOI 10.1002/1096-911X(20001101)35:5<449::AID-MPO2>3.0.CO

[6]

2-X

[7] Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study [J].

Mahoney, DH ;

Shuster, JJ ;

Nitschke, R ;

Lauer, SJ ;

Steuber, CP ;

Winick, N ;

Camitta, B .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1712-1722

[8] The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production [J].

Morita, Y. ;

Fukazawa, T. ;

Hirashima, M. ;

Kaga, K. ;

Kusaoi, M. ;

Morita, T. ;

Touyama, S. ;

Morita, K. ;

Takasaki, Y. ;

Hashimoto, H. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 (04) :268-272

[9] Drug therapy - Therapeutic strategies for rheumatoid arthritis [J].

O'Dell, JR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2591-2602

[10] Reversible posterior leucoencephalopathy during oral treatment with methotrexate [J].

Renard, D ;

Westhovens, R ;

Vandenbussche, E ;

Vandenberghe, R .

JOURNAL OF NEUROLOGY, 2004, 251 (02) :226-228

← 1 2 →